PD-(L)1 Inhibitors and Anlotinib Boost SCLC Therapy
In the relentless battle against extensive-stage small cell lung cancer (ES-SCLC), medical researchers are continuously seeking therapeutic strategies that offer hope beyond the limited efficacy of current treatment options. Recent findings published in BMC Cancer introduce a promising second-line treatment regimen combining PD-(L)1 inhibitors and anlotinib, which appears to outshine conventional therapies by significantly extending […]
In the relentless battle against extensive-stage small cell lung cancer (ES-SCLC), medical researchers are continuously seeking therapeutic strategies that offer hope beyond the limited efficacy of current treatment options. Recent findings published in BMC Cancer introduce a promising second-line treatment regimen combining PD-(L)1 inhibitors and anlotinib, which appears to outshine conventional therapies by significantly extending […]
What's Your Reaction?
